Literature DB >> 18046710

Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans.

Andreas Schulze1, Philippe Gripon, Stephan Urban.   

Abstract

UNLABELLED: Contrary to many other viruses, the initial steps of the hepatitis B virus (HBV) infection, including attachment to hepatocytes, specific receptor interactions, and membrane fusion, are unsolved. Using HepaRG cells as an in vitro cell culture system, we here report that HBV entry into hepatocytes depends on the interaction with the glycosaminoglycan (GAG) side chains of cell-surface-associated heparan sulfate proteoglycans. Binding to GAGs requires the integrity of the pre-S domain as a part of the large (L-) viral envelope protein. HBV infection was abrogated by incubation of virions with heparin, but not the structurally related GAGs chondroitin sulfate A, B, and C. Infection was also abolished by suramin, a known inhibitor of duck hepatitis B virus infection or highly sulfated dextran sulfate. Polycationic substances such as poly-L-lysine, polybrene, and protamine also prevented infection, however, by addressing cellular components. Enzymatic removal of defined acidic carbohydrate structures from the cell surface using heparinase I/III or the obstruction of GAG synthesis by sodium chlorate inhibited HBV infection of HepaRG cells and, moreover, led to a reduction of HBV cell surface binding sites. The biochemical analysis showed selective binding of L-protein-enriched viral particles (virions or filaments) to heparin. GAG-dependent binding of HBV was improved by polyethylene glycol, a substance that specifically enhances HBV infection.
CONCLUSION: HBV infection requires the initial attachment to the carbohydrate side chains of hepatocyte-associated heparan sulfate proteoglycans as attachment receptors. This interaction initializes the multistep entry process of HBV and cannot be bypassed by alternative routes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046710     DOI: 10.1002/hep.21896

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  149 in total

Review 1.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

Review 2.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

Review 3.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

4.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

5.  Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System.

Authors:  Benjamin Y Winer; Jenna M Gaska; Gabriel Lipkowitz; Yaron Bram; Amit Parekh; Lance Parsons; Robert Leach; Rohit Jindal; Cheul H Cho; Anil Shrirao; Eric Novik; Robert E Schwartz; Alexander Ploss
Journal:  Hepatology       Date:  2019-08-09       Impact factor: 17.425

Review 6.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

7.  Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Authors:  Chee Wah Tan; Chit Laa Poh; I-Ching Sam; Yoke Fun Chan
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.

Authors:  Andreas Schulze; Alexa Schieck; Yi Ni; Walter Mier; Stephan Urban
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 9.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

10.  Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment.

Authors:  Alina Macovei; Catalina Petrareanu; Catalin Lazar; Paula Florian; Norica Branza-Nichita
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.